Sign in or Register   Sign in or Register
  |  

Mouse Anti-MSLN Recombinant Antibody (1A10) (CBMAB-A5624-LY)

The product is antibody recognizes MSLN. The antibody 1A10 immunoassay techniques such as: WB, ELISA.
See all MSLN antibodies
Published Data
Fig.1 MSLN expression in tumors excised from vehicle and RG7787-treated mice was examined by IHC in formalin-fixed paraffin-embedded tissue.
...View More

Summary

Host Animal
Mouse
Specificity
Human
Clone
1A10
Antibody Isotype
IgG2b, κ
Application
WB, ELISA

Basic Information

Immunogen
MSLN (NP_005814, 464 a.a. ~ 563 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Specificity
Human
Antibody Isotype
IgG2b, κ
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Purity
> 95% Purity determined by SDS-PAGE.
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freezethaw cycles.

Target

Full Name
Mesothelin
Introduction
An antibody that reacts with ovarian cancers and mesotheliomas was used to isolate a cell surface antigen named mesothelin. Although the function of mesothelin is unknown, it may play a role in cellular adhesion and is present on mesothelium, mesotheliomas, and ovarian cancers. This gene encodes a preproprotein that is cleaved into two products, megakaryocyte potentiating factor and mesothelin. Alternative splicing results in multiple transcript variants. [provided by RefSeq]
Entrez Gene ID
10232
UniProt ID
Q13421
Alternative Names
CAK1; MPF; SMR
Function
Membrane-anchored forms may play a role in cellular adhesion.

Megakaryocyte-potentiating factor (MPF) potentiates megakaryocyte colony formation in vitro.
Biological Process
Cell adhesion Source: UniProtKB
Cell-matrix adhesion Source: GO_Central
Pancreas development Source: Ensembl
Cellular Location
Plasma membrane
Cell membrane
Golgi apparatus
Megakaryocyte-potentiating factor:
Secreted
Isoform 3:
Secreted
Involvement in disease
Antibodies against MSLN are detected in patients with mesothelioma and ovarian cancer.
PTM
Both MPF and the cleaved form of mesothelin are N-glycosylated.
Proteolytically cleaved by a furin-like convertase to generate megakaryocyte-potentiating factor (MPF), and the cleaved form of mesothelin.

Hagerty, B. L., & Takabe, K. (2023). Biology of Mesothelin and Clinical Implications: A Review of Existing Literature. World Journal of Oncology, 14(5), 340.

Wang, Q., & Gong, R. (2022). Immunotherapy targeting mesothelin in acute myeloid leukemia. Journal of Leukocyte Biology, 112(4), 813-821.

Schoutrop, E., El-Serafi, I., Poiret, T., Zhao, Y., Gultekin, O., He, R., ... & Mattsson, J. (2021). Mesothelin-specific CAR T cells target ovarian cancer. Cancer Research, 81(11), 3022-3035.

Klampatsa, A., Dimou, V., & Albelda, S. M. (2021). Mesothelin-targeted CAR-T cell therapy for solid tumors. Expert opinion on biological therapy, 21(4), 473-486.

Weidemann, S., Gagelmann, P., Gorbokon, N., Lennartz, M., Menz, A., Luebke, A. M., ... & Simon, R. (2021). Mesothelin expression in human tumors: a tissue microarray study on 12,679 tumors. Biomedicines, 9(4), 397.

Kaeding, A. J., Barwe, S. P., Gopalakrishnapillai, A., Ries, R. E., Alonzo, T. A., Gerbing, R. B., ... & Meshinchi, S. (2021). Mesothelin is a novel cell surface disease marker and potential therapeutic target in acute myeloid leukemia. Blood Advances, 5(9), 2350-2361.

Montemagno, C., Cassim, S., Pouyssegur, J., Broisat, A., & Pagès, G. (2020). From malignant progression to therapeutic targeting: current insights of mesothelin in pancreatic ductal adenocarcinoma. International Journal of Molecular Sciences, 21(11), 4067.

Shen, J., Sun, X., & Zhou, J. (2020). Insights into the role of mesothelin as a diagnostic and therapeutic target in ovarian carcinoma. Frontiers in Oncology, 10, 1263.

Hagemann, U. B., Ellingsen, C., Schuhmacher, J., Kristian, A., Mobergslien, A., Cruciani, V., ... & Cuthbertson, A. S. (2019). Mesothelin-targeted thorium-227 conjugate (MSLN-TTC): preclinical evaluation of a new targeted alpha therapy for mesothelin-positive cancers. Clinical Cancer Research, 25(15), 4723-4734.

Lv, J., & Li, P. (2019). Mesothelin as a biomarker for targeted therapy. Biomarker Research, 7(1), 1-18.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-MSLN Recombinant Antibody (1A10)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare